How we contribute to the World AMR Awareness Week
From 18 to 24 November, World AMR Awareness Week 2026 brings together human, animal and environmental health under the theme “One Health, one action: Prevent AMR nowâ€�. At the Laboratory of Medical Microbiology, 91³Ô¹ÏÍø, we fully support the campaign and embrace this year’s theme, which reflects how we have worked with partners across sectors to tackle antimicrobial resistance. For and the colleagues in her research group, that means tracking resistant bacteria across settings, developing tests that can inform treatment, and working with partners to turn those findings into better prevention. The team’s work spans four connected research areas: One Health surveillance, precision and point-of-care diagnostics, host–pathogen interactions, and population biology, which we explore below through recent achievements and the perspectives of the people behind the research.
One Health surveillance for infections and resistance: Following resistant bacteria through hospitals and food systems
Through and projects, the team of Prof. Malhotra-Kumar and its partners are contributing to clinical and microbiological surveillance in neonatal units across sub-Saharan Africa and Europe to inform research on better treatments for severe infections in newborns and to understand how the neonatal care environment may contribute to colonisation and infection.
In a 2026 NeoIPC published in JAMA Network Open, researchers surveyed 24 neonatal units across eight European countries. Infants were more likely to acquire gut colonisation with ESBL-producing bacteria in units where a higher proportion of babies already carried them. This association persisted after accounting for prematurity, length of stay and prior antibiotic exposure. The findings highlight the value of tracking which bacteria babies carry, even in the absence of symptoms, to guide infection prevention across the unit.
Surveillance also helps identify where prevention efforts can make a difference. In a 2026 study published in Microbial Genomics, the team of Prof. Malhotra-Kumar and its partners used genome sequencing to show that a lineage of Klebsiella pneumoniae had persisted in a Berlin hospital for years. Some bacteria recovered from sinks were genetically related to those found in patients, pointing to the care environment as a possible reservoir. The study shows what long-term surveillance can reveal: cases separated in time may be part of the same pattern, with implications for where infection prevention teams look for sources of transmission.
The group took that same comparative approach beyond the hospital in a with Vietnamese public health, clinical and veterinary partners, published in Clinical Microbiology and Infection. The dominant resistant Escherichia coli lineages differed between human and food-chain samples, even though some resistance gene variants appeared in more than one source. Looking at both the bacteria and the genes they carry helped distinguish shared resistance from the spread of a single bacterial lineage. That distinction matters when deciding where to investigate and how to intervene.
These studies illustrate why we support the campaign’s One Health focus. The settings in which we look for resistance shape what we can learn about its spread. In our neonatal work, we’ll continue to bring together genomic findings and surveillance data from infants and their care environment to help clinical and infection control teams decide where to investigate possible transmission.
Developing precision and point-of-care diagnostics: Getting the right information to clinicians sooner
A test can support appropriate antibiotic use when it delivers an answer in time to guide care. In 2026, Prof. Malhotra-Kumar and colleagues contributed to a joint European Respiratory Society and European Society of Clinical Microbiology and Infectious Diseases examining where rapid tests can help guide care for community-acquired lower respiratory tract infections. At 91³Ô¹ÏÍø, the team has also worked on using long-read sequencing to identify pathogens directly from respiratory samples, with the aim of supporting earlier, more targeted treatment. Precision diagnostics can also help identify who is at risk before symptoms develop. In an Antwerp-led published in Nature Communications, researchers identified differences in the gut microbiome before antibiotic treatment that were associated with subsequent Clostridioides difficile infection. Those findings provide a basis for developing tests that could identify patients at higher risk of this antibiotic-associated complication.
Host–pathogen interactions in respiratory infections
Why do bacteria cause infection in some patients while others carry them without symptoms? In a European multicentre published in Clinical Microbiology and Infection in 2025, intensive care patients carrying Pseudomonas aeruginosa were more likely to develop pneumonia caused by that bacterium. The finding raises a question at the heart of the team’s research: what tips the balance from carriage to infection?
The team studies how bacteria such as P. aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis interact with airway tissues and with one another. Using sequencing and experimental models, including organ-on-chip systems, researchers aim to understand which interactions help pathogens establish an infection and which help keep them in check. The goal is to identify opportunities to prevent respiratory infections in patients on mechanical ventilation.
Research spotlight — IHI highlights an Antwerp-led study on how P. aeruginosa adapts during antibiotic treatment. The Innovative Health Initiative (IHI) featured the 2026 npj Antimicrobials and Resistance in its and highlighted it in a . The researchers tracked P. aeruginosa in samples collected over time from 25 mechanically ventilated intensive care patients. They found that when the bacterium became more resistant to certain antibiotics, it sometimes became more susceptible to others. This trade-off, known as collateral susceptibility, is a question for future antibiotic stewardship studies: can changes in susceptibility during treatment help clinicians decide which antibiotic to use next?
Population biology of microbiomes and antibiotic resistance
The gut microbiome is a community of bacterial populations that compete for space and nutrients. In a healthy gut, that competition can make it harder for incoming pathogens to establish themselves. Antibiotics can shift the balance by reducing some populations and allowing others to expand. The team studies what drives those shifts, how microbial communities recover and what these changes mean for the persistence of antibiotic resistance.
A central question is how much of the increase in resistance comes from the expansion of bacteria that already carry resistance genes, and how much comes from those genes passing between bacteria. 91³Ô¹ÏÍø team’s recent highlights how microbiome population dynamics, ecological interactions, and horizontal gene transfer jointly shape the emergence and persistence of antimicrobial resistance within microbial communities, providing a population biology framework for understanding resistance evolution in the gut microbiome.
The team aims to combine gut-on-a-chip models with single-cell sequencing to examine both processes and understand when the gut microbiome is most vulnerable to losing its protective role.
This World AMR Awareness Week, we reaffirm our commitment to turning research into better prevention, diagnosis and treatment of infections. Across our four research areas, progress depends on the people behind the work and the partnerships that connect disciplines, countries and sectors. United by the call “One Health, one action: Prevent AMR now�, we combine our expertise as one team and work with our partners to turn shared knowledge into action.